Tag: Psoriasis

Safety and Efficacy of a Halobetasol 0.01%/Tazarotene 0.045% Fixed Combination Lotion in the Treatment of Moderate-to-severe Plaque Psoriasis: A Comparison with Halobetasol Propionate 0.05% Cream

 J Clin Aesthet Dermatol. 2018;11(11):15–19 by Neal D. Bhatia, MD; David M. Pariser, MD; Leon Kircik, MD; Tina Lin, PharmD; Susan Harris, MS; Lindsey Mathew; and Radhakrishnan Pillai, PhD Dr. Bhatia is with Therapeutics Clinical Research in San Diego, California. Dr. Pariser is with Virginia Clinical Research, Inc. in Norfolk, Vriginia. Dr. Kircik is with


A Case-control Study to Evaluate the Prevalence of Nonalcoholic Fatty Liver Disease Among Patients with Moderate-to-severe Psoriasis

by Olabola Awosika MD, MS; Misty G. Eleryan MD; Monica Rengifo-Pardo MD; Lindsay Doherty MS; Lisa W. Martin, MD; and Alison Ehrlich MD, MHS Drs. Awosika, Rengifo-Pardo, and Ehrlich are with the Department of Dermatology, The George Washington Medical Faculty Associates in Washington, DC. Dr. Martin is with the Department of Cardiology, The George Washington Medical